An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of ND-003 in Patients With Advanced Solid Cancers

PHASE1Enrolling by invitationINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

February 4, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

June 30, 2026

Conditions
Advanced Solid Tumor
Interventions
DRUG

ND-003 tablets

ND-003 tablets will be administered orally and observe 4 days, and followed by over continuous 28-days cycles.

DRUG

ND-003 tablets

ND-003 tablets will be administered orally and observe 4 days, and followed by over continuous 28-days cycles.

DRUG

ND-003 tablets

ND-003 tablets will be administered orally and observe 4 days, and followed by over continuous 28-days cycles.

DRUG

ND-003 tablets

ND-003 tablets will be administered orally and observe 4 days, and followed by over continuous 28-days cycles.

DRUG

ND-003 tablets

ND-003 tablets will be administered orally and observe 4 days, and followed by over continuous 28-days cycles.

DRUG

ND-003 tablets

ND-003 tablets will be administered orally and observe 4 days, and followed by over continuous 28-days cycles.

DRUG

ND-003 tablets

ND-003 tablets will be administered orally over continuous 28-days cycles.

DRUG

ND-003 tablets

ND-003 tablets will be administered orally over continuous 28-days cycles.

Trial Locations (21)

Unknown

the First Affiliated Hospital of Xiamen University, Xiamen

Gansu Provincial Cancer Hospital, Lanzhou

the first hospital of Lanzhou University, Lanzhou

Sun Yat-sen University cancer center, Guangzhou

The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou

Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center, Shenzhen

Zhanjiang Central Hospital, Guangdong Medical University, Zhanjiang

Guangxi Medical University Cancer Hospital, Nanning

the Affiliated Hospital of Guizhou Medical University, Guiyang

Tongji Hospital Tongji Medical College of HUST, Wu’an

Hunan Cancer Hospital, Changsha

Jiangxi Cancer Hospital, Nanchang

The First Hospital of China Medical University, Shenyang

General Hospital of Ningxia Medical University, Yinchuan

Shandong Cancer Hospital & Institute, Jinan

Linyi Cancer Hospital, Linyi

Sichuan Cancer Hospital, Chengdu

The Second People's Hospital of Neijiang, Neijiang

Tianjin Medical University Cancer Institute & Hospital, Tianjin

Yunnan Cancer Hospital, Kunming

Sir Run Run Shaw Hospital, Hangzhou

All Listed Sponsors
collaborator

Shenzhen Innovation Center for Small Molecule Drug Discovery Co., Ltd.

UNKNOWN

collaborator

Sun Yat-sen University

OTHER

lead

Shenzhen NewDEL Biotech, Co., Ltd

INDUSTRY